Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multicenter, nonrandomized, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy: Results in malignant pleural mesothelioma (MPM)
    Meeting Abstract

    Trigo Perez, J. M.; van Brummelen, E.; Levchenko, E.; Domine Gomez, M.; Fennell, D. A.; Kindler, H. L.; Viteri, S.; Gadgeel, S.; Garrido Lopez, P.; Kostorov, V.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Updated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies
    Meeting Abstract

    Tsurutani, J.; Doi, T.; Iwata, H.; Takahashi, S.; Modi, S.; Tamura, K.; Shitara, K.; Taniguchi, H.; Taira, S.; Li, B.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C
    Meeting Abstract

    Rai, R.; Ezeoke, O. M.; McQuade, J. L.; Zimmer, L.; Koo, C.; Park, J. J.; Ardolino, L.; Yip, D.; Goldinger, S.; Cohen, J. V.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • KEYNOTE-604: Phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC)
    Meeting Abstract

    Rudin, C. M.; Shen, L.; Pietanza, M. C.
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • LKB1 loss is a novel genomic predictor of de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma
    Meeting Abstract

    Skoulidis, F.; Hellman, M. D.; Awad, M.; Gainor, J. F.; Rizvi, H.; Carter, B.; Denning, W. L.; Villalobos, P.; Parra, E. R.; Elamin, Y. Y.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Results of a randomized, placebo-controlled, phase 2 study of tarex-tumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)
    Meeting Abstract

    Daniel, D. B.; Rudin, C. M.; Hart, L.; Spigel, D. R.; Edelman, M. J.; Goldschmidt, J.; Bordoni, R.; Glisson, B.; Burns, T. F.; Dowlati, A.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC
    Meeting Abstract

    Drilon, A. E.; Liu, S.; Doebele, R.; Rodriguez, C.; Fakih, M.; Reckamp, K. L.; Bazhenova, L.; Cho, B. C.; Kowack, E.; Oliver, J.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1 study of oral LOXO 292 in adult patients with advanced solid tumors, including RET-fusion non-small cell lung cancer, medullary thyroid cancer and other tumors with increased RET activity
    Meeting Abstract

    Drilon, A. E.; Bauer, T. M.; Subbiah, V.; Cabanillas, M.; Lahkani, N.; Wirth, L.; Oxnard, G.; Smith, S.; Eary, T.; Cruickshank, S.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: Expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1
    Journal Article

    Eguchi, T.; Kadota, K.; Mayor, M.; Zauderer, M. G.; Rimner, A.; Rusch, V. W.; Travis, W. D.; Sadelain, M.; Adusumilli, P. S.
    Oncotarget (2017)

    Fulltext@MSK | Save
  • Antiemetics: American Society of Clinical Oncology clinical practice guideline update
    Journal Article

    Hesketh, P. J.; Kris, M. G.; Basch, E.; Bohlke, K.; Barbour, S. Y.; Clark-Snow, R. A.; Danso, M. A.; Dennis, K.; Dupuis, L. L.; Dusetzina, S. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save